A humanised bi-specific BiTE antibody (bi-specific T-cell engaging), able to bind both CSPG4 and human CD3 to engage the T cell receptor (TCR) complex, was designed to redirect CD3+ T cells (especially CTL) against melanoma cells (45). Here, CSPG4 is linked to melanoma.